We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
there's a chance the seller has stopped selling.. I'm a good ways from sure on that mind you.. the only way to find out is buy trades going through in numbers not matched by strong selling ?
Here's hoping..
Armistice Capital selling hard their ADR's seems to me to be at the root of recent ongoing share price weakness ??
Disappointing !!
But there seems to be pretty willing size buyer(s) to counter those sells too.. and large stocks of ammo expended by Armistice now ?? (3.4% holding down to .46% recently for eg and selling today too seemingly .. if I'm interpreting the RNS's correctly.. I may not be ?)
Hopefully if/when they're stopped there are no more size sellers.. and more potential buyers are encouraged to get back buying here..
I'd offer that 'themarketseer' is not seeing clearly at all on this one.
Time for an eye test?
They've just done a raise and so their cash runway is as long as it generally gets... and I'd expect that another raise would get done too, whenever in 21 or 22 (at a punchy discount to s/p at that time, of course)
Good news of tangible short term income related nature would do wonders for this now very low s/p imho :
eg
that EU grant actually coming through in the end
or
a development partner coming on board, including cash injection for a drug or technology progression
or
a new licencing agreement ideally including some sort including upfront payment
or
sale of one or multiple asset(s)
or
sale of the company outright
If /when that recent seller is out of bullets, any sort of decent buying momentum here would beget more buying again quickly imho .. and a good rally ensue.
If Haso and mates are reading here still, I offer:
Buy low. Sell high. You know it makes sense !!!!!
Thank you CJ39
Yes rampers and derampers are widespread on these boards. As Lse only take token action against these cretins it’s unlikely we will ever see the back of them.
Dodger777 - many apologies. I re-read your post and can see you were sarcastically saying “it’s guaranteed is it?” Sorry about that.
I just hate rampers. I got caught out in the past by them, they really are shocking for what they do and want to put them.
And while I’m here....as for ‘themarketseer’ lol ..profile created today...move along you deramping cretin. I assume like ‘big brenda’ you were deleted by lse previously and now popped in before you are deleted again to spread your wisdom...
And CJ39....I await my apology....
ummm..could the original poster of this thread check before they post ....big Brenda aka a ramper that was deleted from the lse boards said 40p....while I sarcastically was asking where was the 40p.
Before you accuse someone of ramping bullsh*t check your facts first....I expect an apology
Sent an email to MTPH regarding the message below and asking for any news to lift the SP
to be RNS'ed.
Themarketseer....wtf, jacket, padded walls, door closed, nite, nite
I would say most posters on here are aware that potential buyers could just play a waiting game and let the cash runway fade away. Maybe that’s one of the reasons why Stamp has attempted to lengthen it with the raise? Would IIs put £4.3 million if they thought administration was already unavoidable? With administration also comes the risk that the intellectual property (patents etc.) will pass to the Crown as bona vacantia.
You mention that “their top priority/most valuable asset isn't even theirs.” Well, none of the drugs Midatech develop are theirs. That is the whole point of Midatech – they use their three technologies (which they do own) to make already approved drugs perform better. MTX110 is panobinostat (Farydak) – developed by Novartis. In March 2019, Secure Bio obtained global commercialisation rights for Farydak from Novartis to treat patients with multiple myeloma, the only indication for which it is approved. In June 2017, Midatech signed a global license agreement with Novartis to investigate panobinostat for treatment of brain cancers. MTX110 received orphan designation for DIPG in October 2019.
I have only read the original RNS announcing the license agreement with Novartis, and it is not detailed. You indicate it is now “on a questionable license tenure with the new US owners” and the “original license terms of MTX-110 are too onerous to distribute the drug worldwide especially Asia which was the major shareholder's objective.” It would help if you could expand on this in a bit more detail and explain where we can access this information.
You say MTD201 has been demoted to second class status. How do you know that?
Guys...this is the reality. This company is headed straight to ts destination: administration. Don't doubt it. Buyers of the assets they want, if they want them, know they will buy them much cheaper simply by waiting for this inevitable train crash to happen. Assets? Their top priority/most valuable asset isn't even theirs, is on a questionable license tenure with the new US owners after the divestiture by Novartis. The original license terms of MTX-110 are too onerous to distribute the drug worldwide especially Asia which was the major shareholder's objective. Their other drug, which has now been relegated to second class status after holding out so much promise (why?) isn't getting a market bid for it or the company. Go figure. The ex CEO has gone to Herantis, and guess who was a non exec director there? None other than Jim Phillips. Yes, him. Smart money is waiting for administration. Don't expect a bid anytime soon. The market seems to agree.
Stayed = stated.
On the 18th May when the share price fell to 28.5p you both stayed that the share price will be guaranteed to be 40p the following day. I’ve come back to see if you were right. You were both totally wrong.